Avadel Pharmaceuticals PLC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Alkermes CEO Richard Pops sent a message to Avadel Pharmaceuticals employees, expressing excitement for the upcoming acquisition and integration, and outlining future plans.
Avadel Pharmaceuticals announced the expiration of the HSR Act waiting period, satisfying a key condition for its acquisition by Alkermes.
Avadel Pharmaceuticals shareholders are invited to vote on Alkermes' proposed acquisition for $21.00 cash plus a $1.50 CVR per share, valuing the company at up to $2.37 billion.
Avadel Pharmaceuticals and Alkermes plc have amended their acquisition agreement, increasing the offer to up to $22.50 per share, with Avadel's Board reaffirming its recommendation for Alkermes.
Alkermes plc has increased its recommended offer to acquire Avadel Pharmaceuticals plc to up to $22.50 per share, a move prompted by a competing proposal from H. Lundbeck A/S.
Avadel Pharmaceuticals' Board of Directors has determined that H. Lundbeck A/S's unsolicited acquisition proposal, valued at up to $23.00 per share, constitutes a Company Superior Proposal compared to its existing agreement with Alkermes.
Avadel Pharmaceuticals' Board of Directors has declared an unsolicited acquisition proposal from H. Lundbeck A/S, valuing the company at up to $2.4 billion, as superior to its existing agreement with Alkermes plc.
Avadel Pharmaceuticals plc announced it received an unsolicited acquisition proposal from H. Lundbeck A/S for up to $23.00 per share, potentially challenging its existing agreement with Alkermes.
Avadel Pharmaceuticals' Board deems an unsolicited acquisition proposal from H. Lundbeck A/S for up to $23.00 per share as potentially superior to its existing deal with Alkermes.
Alkermes plc announced its intent to acquire Avadel Pharmaceuticals plc, aiming to expand its neuroscience leadership and sleep disorder portfolio.
Alkermes plc has agreed to acquire Avadel Pharmaceuticals plc for up to $2.1 billion, including a contingent value right, to expand its presence in the sleep medicine market.
Alkermes plc will acquire Avadel Pharmaceuticals plc for up to $20.00 per share, including a contingent value right, to expand its presence in the sleep medicine market.
DEFA14A: Avadel Pharmaceuticals Schedules 2025 Annual Shareholder Meeting, Details Voting and Proxy Access
Avadel Pharmaceuticals plc has announced the details for its 2025 Annual Meeting of Shareholders, including proxy material access, voting procedures, and key proposals for director elections and auditor ratification.
Avadel Pharmaceuticals plc has announced its 2025 Annual General Meeting of Shareholders to be held on July 29, 2025, focusing on the re-election of seven current directors and the ratification of Deloitte & Touche LLP as the company's independent auditor.
Avadel Pharmaceuticals plc will hold its annual shareholder meeting on July 30, 2024, to vote on the election of directors, ratification of the auditor, and executive compensation.
Avadel Pharmaceuticals has announced its 2024 Annual General Meeting, where shareholders will vote on director elections, auditor ratification, and executive compensation.